跳至主要内容
临床试验/NL-OMON46014
NL-OMON46014已完成2 期

Inhibition of salivary glands to reduce uptake and toxicity of PSMA-ligands - Inhibition of Salivary Glands

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Received PSMA PET/CT on clinical indication (<1 month before study date).
  • - At least one PSMA-positive tumour location visible with diameter >1cm.

排除标准

  • - Poor quality of the baseline PSMA PET/CT scan
  • - Planned start or changes in treatment prior to study procedures.
  • - Age < 18y
  • - Inability to provide informed consent
  • - History of disease or treatment involving the salivary glands
  • - Currently on neurotransmitter blocking/stimulating medication
  • - Contra-indications for anticholinergic medication, including glaucoma, obstruction of digestive or urological tract, megacolon, ileus, tardive dyskinesia
  • - (For optional MR-scans only): Standard contra-indications for MR

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验